Maintelyte (Magnesium Chloride Hexahydrate, Potassium Chloride, Sodium Chloride, Glucose, Sodium Acetate Trihydr)

Magnesium chloride hexahydrate supplies magnesium ions that are essential for many enzymatic reactions and cellular functions. In Maintelyte, the magnesium, together with potassium, sodium, acetate and glucose, raises plasma electrolyte concentrations, buffers acid‑base status and draws water into the vascular space, thereby correcting deficits.

The dose of Maintelyte is determined by the prescribing clinician based on the patient’s electrolyte levels, fluid status and clinical condition. The prescriber selects the appropriate volume and infusion rate to safely correct the identified deficiencies.

Safety data for Maintelyte in pregnancy and lactation are limited. It should be used only when clearly needed and after a risk‑benefit assessment by the treating physician. Breastfeeding mothers should consult their healthcare provider before use.

To order Maintelyte, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Maintelyte combines magnesium, potassium, sodium, acetate and glucose in a single sterile IV formulation, offering a broader electrolyte profile than many single‑ion solutions. This can reduce the need for multiple infusions, but selection should consider the specific electrolyte deficits and clinical context compared with alternatives such as standard saline or potassium‑chloride only solutions.

Maintelyte should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture and extreme temperature fluctuations. Inspect the container for any damage before use and discard if the solution appears discolored or particulate.

Maintelyte is administered intravenously by a qualified healthcare professional. The solution is typically infused through a peripheral or central venous line, with the rate adjusted according to the patient’s electrolyte levels, cardiac status and fluid balance. Continuous monitoring is recommended during administration.

Serious risks include severe hypermagnesemia or hyperkalemia, which can cause respiratory depression, cardiac arrhythmias or cardiac arrest, as well as anaphylactic reactions. Prompt recognition of symptoms such as sudden hypotension, respiratory difficulty, irregular heartbeat or severe allergic signs is essential for immediate intervention.

Maintelyte should be avoided in patients with known hypersensitivity to any component, severe renal failure where electrolyte excretion is impaired, uncontrolled cardiac arrhythmias, or in those where rapid fluid expansion could cause pulmonary edema. Clinicians must evaluate each patient’s condition before administration.